Jade Truong
Family · Houston, TXNPI 1588913305
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 119 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $936, 2.4 times the $384 reported in 2021.
Across 119 payments — averaging $25.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$723
- Lilly USA, LLC$386
- Boehringer Ingelheim$356
- Amgen$279
- Bayer$194
- Madrigal Pharmaceuticals$147
- plus $994 from 18 others
What the payments were for
- Food & beverage$3,079100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $723 |
| Lilly USA, LLC | 11 | $386 |
| Boehringer Ingelheim | 17 | $356 |
| Amgen | 11 | $279 |
| Bayer | 10 | $194 |
| Madrigal Pharmaceuticals | 1 | $147 |
| Viiv Healthcare Company | 1 | $109 |
| Calliditas Therapeutics US Inc. | 1 | $99 |
| Amarin Pharma, Inc. | 5 | $98 |
| Novo Nordisk | 5 | $97 |
| Sanofi-aventis U.S. LLC | 4 | $84 |
| Exact Sciences | 3 | $67 |
| Abbott | 3 | $63 |
| Pfizer | 4 | $62 |
| GSK | 4 | $62 |
| Novartis | 3 | $53 |
| Cranial Technologies, Inc | 3 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Edwards Lifesciences | 1 | $33 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Mannkind Corporation | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,079 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $115,570 |
| FarxigaDapagliflozin Propanediol | 48 | $62,532 |
| JardianceEmpagliflozin | 47 | $58,714 |
| MounjaroTirzepatide | 18 | $33,688 |
| TrulicityDulaglutide | 17 | $29,413 |
| EntrestoSacubitril/Valsartan | 11 | $18,203 |
| EliquisApixaban | 12 | $14,225 |
| VascepaIcosapent Ethyl | 17 | $11,846 |
| Atorvastatin Calcium | 313 | $2,448 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 18 | $2,221 |
| Nifedipine ErNifedipine | 36 | $1,162 |
| Losartan Potassium | 121 | $1,117 |
| Amlodipine Besylate | 249 | $1,045 |
| Gabapentin | 76 | $1,012 |
| Fluticasone Propionate | 57 | $927 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $97 | $115,57058 claims |
| Lilly USA, LLCMounjaro, Trulicity | $386 | $63,10235 claims |
| AstraZenecaFarxiga | $723 | $62,53248 claims |
| Boehringer IngelheimJardiance | $356 | $58,71447 claims |
| NovartisEntresto | $53 | $18,20311 claims |
| PfizerEliquis | $62 | $14,22512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.
Other family in Houston
- Robin BeachHouston$428K
- Sarah AguilarHouston$199K
- Margaret WhiteHouston$85K
- Cheryl HaseebHouston$42K
- Kendrick ClackHouston$28K
- David WeirDallas$959K
- April LopezMcAllen$417K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.